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Background: Pulmonary arterial hypertension (PAH) is associated with inflammatory response but it is unknown
whether it is associated with alterations in NNMT activity and MNA plasma concentration. Here we examined
changes in NNMT-MNA pathway in PAH in rats and humans.
Methods: PAH in rats was induced by a single subcutaneous injection of MCT (60 mg/kg). Changes in NNMT
activity in the lungs and liver (assessed as the rate of conversion of nicotinamide (NA) to MNA), changes in
plasma concentration of MNA and its metabolites (analyzed by LC/MS) were analyzed in relation to PAH progression.
PAH was characterized by right ventricular hypertrophy (gross morphology), cardiac dysfunction (by MRI), lung
histopathology, lung ultrastructure, and ET-1 concentration in plasma. NO-dependent and PGI2-dependent function in
isolated lungs was analyzed. In naive patients with idiopathic pulmonary hypertension (IPAH) characterized by
hemodynamic and biochemical parameters MNA and its metabolites in plasma were also measured.
Results: MCT-injected rats developed hypertrophy and functional impairment of the right ventricle, hypertrophy of the
pulmonary arteries, endothelial ultrastructural defects and a progressive increase in ET-1 plasma concentration—findings
all consistent with PAH development. In isolated lung, NO-dependent regulation of hypoxic pulmonary vasoconstriction
was impaired, while PGI2 production (6-keto-PGF1α) was increased. NNMT activity increased progressively in the liver and
in the lungs following MCT injection, and NNMT response was associated with an increase in MNA and 6-keto-PGF1α
concentration in plasma. In IPAH patients plasma concentration of MNA was elevated as compared with healthy controls.
Conclusions: Progression of pulmonary hypertension is associated with the activation of the NNMT-MNA pathway in
rats and humans. Given the vasoprotective activity of exogenous MNA, which was previously ascribed to PGI2 release,
the activation of the endogenous NNMT-MNA pathway may play a compensatory role in PAH.
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1, Endothelin 1; HPV, Hypoxic pulmonary vasoconstriction; IPAH, Idiopathic pulmonary arterial hypertension;
MCT, Monocrotaline; Met4PY, N(1)-methyl-4-pyridone-5-carboxamide; Met2PY, N(1)-methyl-2-pyridone-5-
carboxamide; MNA, 1-methylnicotinamide; MRI, Magnetic resonance imaging; NNMT, Nicotinamide N-
methyltransferase; NO, Nitric oxide; NT-proBNP, N-terminal pro brain-type natriuretic peptide; PAH, Pulmonary
arterial hypertension; PAP, Pulmonary arterial pressure; ΔPAP, The change in pulmonary arterial pressure;
PAR, Pulmonary arterial resistance; PGI2, Prostacyclin; PVP, Pulmonary venous pressure; PWP, Pulmonary wedge
pressure; RAP, Right atrial pressure; RVW/BW, Right ventricular to body weight ratioBackground
Nicotinamide N-methyltransferase (NNMT) transfers the
methyl group from S-adenosylmethionine (SAM) to nico-
tinamide (NA, niacin, vitamin B3), resulting in the forma-
tion of 1-methylnicotinamide (MNA) [1]. MNA is further
metabolized via aldehyde oxidase to N(1)-methyl-4-pyri-
done-5-carboxamide (Met4PY) and N(1)-methyl-2-pyri-
done-5-carboxamide (Met2PY). NNMT activity is localized
mainly in the liver but has also been detected in adipose
tissue, kidney, lung, skeletal muscle, heart and brain [1, 2].
Alterations in NNMT expression and activity occurs
in number of diseases. Most reports are related to can-
cer, whereby increased NNMT activity was linked to
methylation status, histone demethylation and expres-
sion of protumorigenic genes [3, 4]. Altered NNMT ac-
tivity was also associated with multiple other diseases,
for example, Parkinson’s disease, liver cirrhosis, meta-
bolic syndrome and diabetes [5–8]. Interestingly, NNMT
may be either a pathogenetic factor or a protective factor
in these diseases. For example, NMMT in adipose tissue
was proposed to contribute to insulin resistance and
obesity, while NNMT in the liver was protective against
diet-induced alterations in metabolism [5, 9].
A number of other reports have suggested cytoprotec-
tive effects of NNMT activity. Increased activation of the
NNMT-MNA pathway has been suggested to constitute
an adaptive response of skeletal muscle in COPD, pro-
tecting against oxidant stress by reducing the levels of
reactive oxygen species (ROS) [10, 11]. Overexpression
of NNMT improved neuronal cell survival and increased
ATP concentration via mitochondrial mechanisms [12].
Finally, MNA protected against kidney tubular injury
[13] and extended the life span in C. Elegans via an
ROS-dependent signalling mechanism [14].
The mechanisms by which NNMT activity is triggered
and endogenous MNA production is initiated are still
not clear. We previously demonstrated that the initiation
and in early hepatitis, MNA release is linked to the en-
ergy deficit/impaired redox status in hepatocytes, while
in a later phase, MNA release is linked to systemic in-
flammation In turn, during the single bout of exercise
MNA release was IL-6-dependent [15, 16].
We previously suggested that increased NNMT ac-
tivity and increased endogenous MNA concentrationin atherosclerosis and hepatitis correlating with in-
creased PGI2 production may represent a compensa-
tory vasoprotective response associated with vascular
inflammation [16, 17].
Pulmonary hypertension is associated with a robust in-
flammatory response but it is unknown whether it is as-
sociated with alterations in NNMT activity and MNA
plasma concentration. In the present work, we analyzed
changes in the NNMT-MNA pathway in rats with in-
duced pulmonary hypertension and in humans with
idiopathic pulmonary arterial hypertension (IPAH). In
rats activity of NNMT-MNA pathway was analyzed par-
allel to progression of pulmonary hypertension and to
changes in NO- and PGI2-dependent function of pul-
monary circulation. Progression of PAH was investigated
by assessment of right ventricular hypertrophy (gross
morphology), cardiac dysfunction (by MRI), lung histo-
pathology, lung ultrastructure and ET-1 concentration in
plasma, while NO-dependent and PGI2-dependent func-
tion was analyzed in isolated lungs. In humans idio-
pathic pulmonary arterial hypertension (IPAH) was
diagnosed according to the guidelines of the European
Society of Cardiology based on resting hemodynamics
(elevation of mean pulmonary artery pressure at rest to
≥25 mmHg, increased pulmonary vascular resistance > 3
Wood units, and pulmonary wedge pressure ≤15 mmHg)
when predisposing conditions such as connective tissue
disease, HIV infection, congenital heart disease, portal
hypertension and anorexigen exposure were excluded.
Methods
Animals
To induce pulmonary hypertension, male Wistar rats
(180-200 g) were injected with monocrotaline (MCT,
60 mg/kg s.c., Sigma Aldrich) solution. MCT was dis-
solved ex tempore in 1 M HCl, neutralized with 1 M
NaOH and diluted with distilled water. Rats at 7, 14, 21
and 28 days post-MCT injection (1 week, 2 weeks,
3 weeks, 4 weeks post-MCT groups, respectively) were
used to assess endothelial function in the isolated rat lung
set-up (32 rats, n = 8 in each group) via the following mea-
sures: concentration of endothelial mediators in plasma,
right ventricular hypertrophy, right ventricular function as
visualized in vivo through Magnetic Resonance Imaging,
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(40 rats, n = 20 in both groups).
All investigations were performed in accordance with
the Guide for Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health, and the
experimental procedure used in the study was approved
by the local Animal Research Committee (53/2009).
Characteristics of the progression of pulmonary
hypertension pathology in rats injected with MCT
Survival
Rats were injected with MCT solution or saline (n = 20
for both groups), and housed in two groups with food
and water ad libitum. The animals were weighed every
day of the experiment and observed continuously.
Assessment of right ventricular hypertrophy and
collection of tissue
The rats were weighed and anesthetized with thiopental
(120 mg/kg). The chest was opened and blood was taken
from right ventricle into a syringe containing citrate so-
dium solution (3.15 %). The obtained blood samples
were immediately centrifuged (12000 rpm, 10 min) and
then immediately frozen and kept at -80 °C until ana-
lysis. The heart was removed from the chest wall, the
right ventricle was separated from the left ventricle and
septum and was weighed. Right ventricular hypertrophy
was calculated as the right ventricle to body weight ratio
(RVW/BW). The lungs and liver were washed in saline,
immediately frozen in liquid nitrogen and kept at -80 °C
until analysis.
Assessment of histopathological and ultrastructural
changes of the lungs
For histopathology, whole lungs were dissected and fixed
immediately in 10 % buffered formalin (pH 7.4) for about
24 h at room temperature. They were then washed for
2 h, dehydrated through a graded ethanol series, placed in
xylene (3 times for 15 min), embedded in paraffin (58 °C,
3 h), and cast into blocks. Tissue samples were cut into
approximately 5 mm thick sections by microtome, placed
on glass slides and stained by hematoxylin and eosin.
Light microscopic examination and photographic docu-
mentation were performed using a Zeiss microscope.
For electron microscopy (EM), lung tissue was dis-
sected and fixed immediately using a mixture of 2.5 %
glutaraldehyde, 2 % freshly prepared paraformaldehyde
in 0.1 mol/L cacodylate buffer at pH 7.4. The lung tissue
was fixed for 4-6 h at room temperature. Subsequently,
5-10 pieces of lung tissue were gently dissected and fixed
at room temperature for another 24 h. After rinsing with
0.1 mol/L cacodylate buffer (12 h), lung tissue blocks
(approximately 3 × 3 × 3 mm3) were post-fixed, dehy-
drated, and embedded in Spur resin by routineprocedure [18]. Lung ultrastructure was viewed and
photographed using Transmission EM Jem 1200 Ex.
Assessment of cardiac function in vivo using Magnetic
Resonance Imaging (MRI)
MRI was performed under inhalation anaesthesia applied
by nose cone (1-2 vol% halothane supplemented by oxy-
gen and air). To assess right and left ventricular function
in rats, we adapted a method of examination of left ven-
tricular function in mouse described elsewhere [19, 20].
MRI system was used consisted of a 4.7 T/310 magnet
(Bruker, Germany), MARAN DRX console (Resonance
Instruments Ltd, UK), ID 90 mm gradients (Resonance
Research, Billerica, MA, USA), and a homebuilt 8-rung
quadrature RF birdcage coil. An ECG trigger unit (SA
Instruments Inc., USA) was used. Halothane was used
to induce and maintain anaesthesia via a nose cone
(at concentrations of 3 % and 0.5-0.7 %, respectively).
The rats were placed in a supine position in the pro-
behead and their temperature was stabilized by flow-
ing warm air at 35 °C [21].
MR imaging was performed using an ECG triggered
fast gradient echo (cine-like flow compensated FLASH)
sequence. For the assessment of right (RV) and left (LV)
ventricular function, at least 20 frames per cardiac cycle
were acquired in short axis with the following imaging
parameters: echo time (TE) 2.5 ms, acquisition matrix
128x128, field of view (FOV) 40x40 mm, slice thickness
1.5 mm, number of scans (NS) 8, and flip angle set to
achieve the best contrast between myocardium and
blood pool (about 30°). Whole ventricles were covered
slice-by-slice.
Both right and left ventricle slice volumes were evalu-
ated using areas of endocardium delineated in Scion
Image (4.0, National Institute of Health, USA). These
volumes were summed to obtain end-systolic (ESV) and
end-diastolic volumes (EDV) of the right and left ventri-
cles. Ejection fraction (EF) was calculated according to
the following formula: EF = [(EDV − ESV)/EDV] × 100 %.
Assessment of the progression of endothelial dysfunction
in isolated perfused rat lung
The isolated lung preparation
Lungs were isolated from Wistar rats weighing 200-
250 g (Lod:WIST BR form Animal Laboratory of Polish
Mothers Memoria Research Institute, Hospital in Łódź,
Poland). In anesthetized rats (thiopental 120 mg/kg, i.p.),
the trachea was cannulated and the lungs were venti-
lated with positive pressure at a rate of 80 breaths/min
(VCM module from Hugo Sachs Electronic-HSE). After
laparothomy, the diaphragm was cut and nadroparine at
a dose of 600 I.U. was injected into the right ventricle to
prevent microthrombi formation during surgery. The
animals were then exsanguinated by incision of the left
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nothomy. The pulmonary artery and left atrium were
cannulated via the right and left atria, respectively.
Immediately after cannulation, the lung/heart block
was dissected from the thorax. Using a tracheal cannula,
the isolated lung was mounted in a water-jacketed (38 °C),
air-tight glass chamber (HSE), and ventilated with negative
pressure. Using a peristaltic pump (ISM 834, HSE), the
lungs were perfused with Krebs-Henseleit buffer (KH-buf-
fer; composition (in mM): NaCl 118, KCl 4.7, KH2PO4 1.2,
MgSO4 1.2, CaCl2 2.5, NaHCO3 12.5, 4 % albumin, 0.1 %
glucose and 0.3 % HEPES; pH of perfusate maintained at
7.35 throughout experiment by continuous addition of
5 % CO2 to the inspiratory air) at a constant flow of about
12.30 ml/min. The lungs were washed with 100 ml KH-
buffer and recirculated with fresh buffer in the buffer-
perfused isolated lung portion of experiments. In the
blood-perfused lungs, blood perfusion was initiated imme-
diately after mounting the isolated lung in the air-tight
glass chamber. The venous pressure was set between 2-
5 cm H2O. The end-expiratory pressure in the chamber
was set to -2 cm H2O and inspiratory pressure was ad-
justed between -6 and -10 cm H2O to yield an initial tidal
volume (TV) of about 2.0 ml. Breathing frequency was set
to 80 breaths/min and the ratio of inspiration length to
expiration length was 1:1 for each breath. Every 5 min
throughout the experiments, a deep breath with end-
inspiratory pressure of -18 cm H2O was automatically
initiated by the VCM module (HSE) to avoid atelectasis.
The inspired air was moisturized by bubbling through
water. Airflow velocity was measured using a pneumo-
tachometer tube connected to a differential pressure
transducer (HSE), from which the respiratory tidal volume
was determined.
Both arterial and venous pulmonary pressures (PAP,
PVP) were continuously monitored with ISOTEC pres-
sure transducers (HSE) connected to perfusion lines on
the arterial and venous sides, respectively. Lung weight
was monitored using a specially designed transducer
(HSE). TC, PAP, PVP and lung weight data were acquired
by the PC transducer card and subsequently analyzed by
Pulmodyn-pulmo software (HSE), as well as continuously
recorded on Graphtec linear recorder WR 3310.
All lungs preparations were allowed to equilibrate for
the first 15 min until stable baseline PAP, PVP, and TV
were achieved. At this time point, lung weight (which var-
ied considerably between experiments) was set to zero.
Assessment of NO- and PGI2-dependent function in the
isolated perfused rat lung
Endothelial function in the isolated perfused lungs of
rats was assessed on the basis of the magnitude of NO-
dependent attenuation of hypoxic pulmonary vasocon-
striction (HPV), and concentration of 6-keto-PGF1α inthe lung effluent. In addition, 6-keto-PGF1α in the
plasma of MCT-injected rats was measured.
Hypoxic pulmonary vasoconstriction (HPV) was
evoked via 10-min intervals of hypoxic ventilation using
a mixture of 95 % N2 and 5 % CO2. Hypoxia-induced
vasoconstriction, measured as changes in PAP, stabilized
after 5 min to a constant level. After cessation of acute
hypoxia, PAP went back to baseline levels. Ten-minute
intervals of normal ventilation occurred between each
HPV procedure. After the initial induction of HPV
followed by normal ventilation, the procedure was re-
peated twice. L-NAME (300 μM) was then added to the
perfusate and perfused through the lung for 10 min,
followed by two additional HPV/normal ventilation cy-
cles. The addition of L-NAME did not result in lung
oedema. Although TV, PAP, PVP and weight were con-
tinuously monitored throughout the experiment, only
the maximum increase in PAP (ΔPAP) elicited by HPV
was used for analysis. TV, PVP and weight did not
change significantly in response to acute hypoxia in the
lungs of either control or MCT-treated animals.
The concentration of 6-keto-PGF1α was determined in
the effluent of the isolated perfused lung and, for com-
parison, in the plasma of rats injected with MCT. To
obtain plasma, blood was taken from the right ventricle
into a syringe containing citrate sodium solution
(3.15 %). The obtained blood samples were immediately
centrifuged (12000 rpm, 10 min) and then immediately
frozen and kept at -80 °C until analysis. PGI2 production
in the effluent from isolated rat lung and in plasma was
quantified by the measurement of 6-keto-PGF1α concen-
tration using a commercially available EIA kit (R&D).
Results are expressed in pg/ml.
Measurement of ET-1 concentration in plasma
ET-1 concentration was measured using a high perform-
ance liquid chromatography tandem mass spectrometry
(LC/MS) method. An HPLC Agilent 1100 (Agilent
Technologies, Waldbronn, Germany) coupled to an API
2000 triple quadrupole mass spectrometer (Applied
Biosystems MDS Sciex, Concord, Ontario, Canada)
equipped with an electrospray ionization interface was
used and measurements were performed in positive
ionization mode. Chromatographic separation was carried
out with an XTerra C18 analytical column (30 mm x
2.1 mm, 3.5 μm, Waters, Ireland) at 20 °C. As an internal
standard, acetyl-[DTrp16]-Endothelin-1, fragment 16-21
was used.
Briefly, sample preparation consisting of the
deproteinization of proteins to ethanol was used for
ET-1 isolation and after centrifugation, evaporation to
dryness and redissolving a sample volume of 25 μL
was injected into the analytical column for peptide
analysis. Chromatography was performed on a reversed
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mobile phase acetonitrile and water with the addition of
0.01 % of formic acid. The tandem mass spectrometer was
operated at unit mass resolution in the selected reaction
monitoring mode, monitoring the transition of the pro-
tonated molecular ions [M + 3H]3+ (m/z 832) to the
product ion (m/z 318) for ET-1, with m/z 887 to m/z
228 for internal standard. The peak widths of the pre-
cursor and product ions were set to 0.7 full width,
half-height. Quantification analysis was performed by
looking at the peak area ratio of ET-1 to IS. The re-
sults showed linearity of the calibration curves from 1
to 200 nM in Krebs-Henseleit buffer and from 21 to
220 nM in polled rat plasma. The limit of detection
of the assay in SRM mode using matrix buffer was
estimated at 40 pM. The limit of quantification of
ET-1 in matrix buffer was established to be 1 nM.
Data acquisition and processing were accomplished
using Applied Biosystems Analyst version 1.4.2 soft-
ware. This method is described in greater detail else-
where [22].
Assessment of NNMT-MNA pathway
Assessment of NNMT activity in the lungs and liver
To evaluate NNMT activity, tissue extracts were assayed
for the enzymatic conversion of NA to MNA in the
presence of cofactor S-adenosyl-L-methionine (SAM),
using liquid chromatography mass spectrometry (LC/MS).
Briefly, lung and liver samples were collected and washed
with cold 0.9 % (w/v) sodium chloride and kept at -80 °C.
The tissue was homogenized 1:9 (w/v) in cold buffer con-
taining 150 mM KCl, 20 mM Tris, 1 mM EDTA, 1 mM
dithiothreitol (pH 7.0) and 0.1 % Triton X-100 using a
teflon-glass homogenizer and was centrifuged at
14000 rpm for 10 min at 4 °C. The supernatant was im-
mediately used to assay NNMTactivity. The reaction mix-
ture consisted of 25 μl 2 mM DTT, 6.25 μl 0.8 M Tris:HCl
(pH 8.6), 12.5 μl 0.8 mM NA, 25 μl 0.4 mM SAM in
0.1 mM sulfuric acid and 50 μl of enzyme preparation.
The mixture was incubated for 20 min at 37 °C and the
reaction was stopped with the addition of 100 μl 1.3 M
HClO4. Blank samples were prepared using the same pro-
cedure, but the reaction was terminated immediately,
without incubation. Each sample was neutralized with
3 M K3PO4, centrifuged and analyzed using LC/MS.
The LC/MS equipment included a Surveyor HPLC
connected to a TSQ Vantage triple quadrupole mass
spectrometer (Thermo Scientific), with heated electro-
spray ionization operating in positive single ion monitor-
ing mode. The column used for separation was Synergy
Hydro-RP (4 μm, 150 x 2.0 mm). The mobile phase was
composed of 10 mM nanofluoropentanoic acid (NFPA)
in water (buffer A) and 100 % acetonitrile (buffer B).
The flow rate was 0.2 ml/min and injection volume was2 μl. NA, MNA, and 2-chloroadenosine, used as an in-
ternal standard, were identified and quantified from
ion transitions m/z 123→ 80 for NA, 137→ 94 for
MNA and 302→ 171 for internal standard, as de-
scribed previously [23].Measurement of plasma concentration of MNA and its
metabolites (Met2PY, Met4PY)
The plasma concentrations of MNA, N(1)-methyl-2-pyr-
idone-5-carboxamide (Met2PY) and N(1)-methyl-4-pyri-
done-3-carboxamide (Met4PY) were determined using
high performance liquid chromatography-mass spec-
trometry (LC/MS). An HPLC Ultimate 3000 (Dionex,
Thermo Scientific, USA) coupled to a TSQ Quantum
Ultra mass spectrometer (Thermo Scientific, USA)
equipped with a heated electrospray ionization interface
(HESI-II Probe) was used. Chromatographic separation
was carried out on an Aquasil C18 analytical column
(4.6 x 150 mm, 5 μm, Thermo Scientific, USA). The mo-
bile phase consisted of acetonitrile with 0.1 % (v/v) for-
mic acid (A) and 5 mM ammonium formate (B). The
flow rate was set at 0.8 mL/min, with isocratic elution
(A:B, 80/20, v/v). The mass spectrometer was operated
in the positive ionization mode using selected reaction
monitoring (SRM). The transitions (precursor to prod-
uct) monitored were m/z 137→ 94 for MNA, m/z
153→ 110 for Met2PY and m/z 153→ 136 for Met4PY.
The transitions (precursor to product) monitored for in-
ternal standards were m/z 140→ 97 for MNA-d3, m/z
156→ 113 for Met2PY-d3 and m/z 156→ 139 for
Met4PY-d3. Data acquisition and processing were accom-
plished using Xcalibur 2.1 software. Plasma samples were
prepared using deproteinization with acidified acetonitrile.Immunohistochemical determination of NNMT in the lungs
and liver
After anaesthesia (thiopental 120 mg/kg, i.p.), small frag-
ments of lung and liver tissue were collected, washed in
PBS solution, and then placed in 50 % OCT solution
(SakuraTek, Japan) overnight for cryoprotection. Sam-
ples were then placed into OCT freezing compound
and snap-frozen at -80○C. OCT frozen liver and lung
tissues were cut into 10 μm-thick cross-sections using
a Leica CM1920 automatic cryostat and placed on
poly-L-lysine-covered microscopic slides (Metzel Glaser
Super Frost). Collected slides were immunostained using
rabbit-anti-mouse NNMT (Abcam) primary antibody,
followed by Cy3-conjugated goat-anti-rabbit secondary
antibody (Jackson Immuno Research). Images were ac-
quired using an AxioCam MRc5 digital camera and an
AxioObserver.D1 inverted fluorescent microscope (Zeiss),
stored as tiff files and analyzed automatically using
Columbus software (version 2.4.2, Perkin Elmer).
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with pulmonary hypertension and controls
We recruited treatment naive, adult patients with newly
diagnosed IPAH who were recorded in our pulmonary
hypertension data base between January 2014 and April
2015. Patients who were ≥18 years old and had blood
samples stored at the time of IPAH diagnosis, were eligible
for the study. We excluded patients who had active infec-
tion or unstable hemodynamics defined as the need for
catecholamine support. All patients were diagnosed ac-
cording to the algorithm recommended by the European
Society of Cardiology. To evaluate the severity of pulmon-
ary hypertension we chose the following parameters: New
York Heart Association class, 6 min walking distance, N-
terminal pro-Brain Natriuretic Peptide (NT-proBNP), and
hemodynamic data including cardiac index (CI) and pul-
monary arterial resistance (PAR).
Patients who were referred to our centre with the sus-
picion of IPAH based on echocardiography and who had
mPAP < 25 mmHg, PAWP ≤15 mmHg, and a cardiac
index (CI) ≥ 2.5 L/min/m2 were taken as controls.
The venous blood samples were taken from each pa-
tient after an overnight fast in the morning on the day
of diagnostic catheterization Blood samples were taken
from the antecubital vein using sodium citrate (0.109 M)
or EDTA as anti-coagulants and centrifuged within one
hour after collection (2500 g, 20 min). Plasma samples
were stored in aliquots frozen until analysis. ET-1, NT-
proBNP and 6-keto-PGF1α concentration in plasma were
measured by ELISA (R&D), while MNA, Met2PY,
Met4PY by LC/MS as described above.
The institutional ethics committee approved the registry
of patients with PAH and the controls including blood
sample storage and both the patients and controls signed
the informed consent (approval no 66/KBL/OIL/2009).
All clinical investigations have been conducted according
to the principles expressed in the Declaration of Helsinki
Statistical analysis
Results are presented as mean ± SEM or median (IQR).
The normality of the results was analyzed using the
D'Agostino & Pearson omnibus normality test and the
Shapiro-Wilk test. To calculate statistical significance, a
paired Student’s t-test, Mann-Whitney test or unpaired
Student t-test was used. Post-hoc analysis was calculated
using Dunn's multiple comparisons test. The survival
was analyzed with the Mantel-Cox's test.
Results
Development of PAH induced by monocrotaline (MCT)
As shown in Fig. 1, injection of MCT resulted in severe
PAH with 100 % mortality (Fig. 1a). Four weeks after
MCT, development of PAH was evidenced by right ven-
tricular hypertrophy (RVW/BW 0.14 ± 0.01 vs 0.07 ±0.01, in post-MCT and Control groups, respectively,
P < 0.05; Fig. 1b), increased ESV (End-Systolic Volume)
and EDV (End-Diastolic Volume), and a decrease in the
EF (Ejection Fraction) of the right ventricle (ESV: 105.41
± 16.07 vs 24.84 ± 3.27 ml, P < 0.05; EDV: 202.80 ± 7.34 vs
77.97 ± 3.91 ml, P < 0.05; EF: 0.48 ± 0.09 vs 0.68 ± 0.02 %,
P < 0.05 for post-MCT and Control groups, respectively;
Fig. 1c, d). In addition, during cardiac contraction, move-
ment of the septum towards the left ventricle was clearly
visible, supporting the presence of increased intraventricu-
lar pressure in the right ventricle compatible with the de-
velopment of PAH 4 weeks after MCT injection. Left
ventricle EF was only modestly affected in advanced PAH
(0.53 ± 0.01 vs 0.65 ± 0.01 % at 4 weeks in post-MCT and
Control groups, respectively, P < 0.05).
The progression of PAH was also evidenced by remodel-
ling of the small pulmonary arteries, with typical thicken-
ing, muscularization and disorganization of the media of
the pulmonary arterial wall associated with inflammatory
cell infiltration around vessels and in the interstitial lung
space (Fig. 1e). Ultrastructural signs of injury to pulmonary
endothelial cells (endothelial oedema, vacuolization and
degeneration), thickening of the subendothelial basal lam-
ina (Fig. 1f), and active formation of novel pulmonary ves-
sels were also compatible with PAH development (Fig. 1f).
Alteration in NO- and PGI2-dependent function in
pulmonary circulation after MCT
PAH was associated with diminished NO-dependent regu-
lation of hypoxic vasoconstriction and increased 6-keto-
PGF1α release. As shown in Fig. 2, the effect of L-NAME
on the magnitude of HPV in post-MCT isolated lungs was
markedly diminished 2 weeks post MCT and completely
abolished 4 weeks post MCT (ΔPAP after HPV+ L-NAME
was 4.71 ± 3.28 vs 31.45 ± 4.33 cm H2O at 4 weeks for
post-MCT and Control groups, respectively, P < 0.01;
Fig. 2a). In turn, the concentration of 6-keto-PGF1α in the
effluent of perfused isolated lung was unchanged at 2 weeks
post MCT but was substantially increased 4 weeks post
MCT (77.13 ± 13.08 vs 51.99 ± 6.24 pg/ml at 4 weeks for
post MCT and Control groups, respectively, P < 0.05)
(Fig. 2b). There was also an approximately 2-fold-increase
in the concentration of 6-keto-PGF1α in plasma 4 weeks
post MCT, as compared to Control (Fig. 2c) as well as in-
crease plasma concentration of ET-1, which is considered a
reliable biomarker of PAH progression (ET-1 in plasma:
91.42 ± 7.63 and 214.95 ± 27.87 vs 47.95 ± 2.67 ng/ml at
2 weeks and 4 weeks for post-MCT and Control groups,
respectively, P < 0.05) (Fig. 2d).
Alterations in NNMT activity in the lungs and liver in
MCT-induced PAH
In control rats, the activity of NNMT in the liver was al-
most 80-fold higher than in the lungs (40.26 ± 2.212 vs
Fig. 1 Development of pulmonary hypertension after injection of MCT in rats. a Survival of rats injected with MCT, with 100 % mortality at 45 days
after MCT injection. b Significant right ventricular hypertrophy (RVW/BW) at 4 weeks after MCT injection (Control n = 10; MCT-treated n = 10 each).
c Impairment of Ejection Fraction (EF) in the right ventricle (RV) and left ventricle (LV) at 4 weeks after MCT injection (Control n = 4; MCT-treated
n = 5 each). d Changes in End-Systolic and End-Diastolic Volume (ESV and EDV) in rats injected with MCT showed increased ESV and EDV until 2 weeks
after MCT injection (Control n = 4; MCT-treated n = 5 each). e Histological image of lung tissue in control rats (upper row) and 4 weeks post-MCT
(bottom row). In the bottom left cross-section with two pulmonary arteries parallel to bronchioles, thickened arteries with massive hypertrophy and
disorganization of vascular smooth muscle cells can be seen – one with a concentric hypertrophic artery and very small lumen; on the bottom-right
picture, horizontal and oblique section of hypertrophic pulmonary artery. f Ultrastructure of lung from rats at 4 weeks after MCT injection. Upper-left
image: degenerated endothelial cell; upper-right: activated endothelial cell with large nucleus and fibrosis of pulmonary tissue; bottom-left:
pathological, multi-layered endothelial cells on thickened basal lamina; bottom-right: neovascularization in lung tissue: two endothelial cells
(EC) surrounded with pericyte on thickened basal lamina. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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lung, respectively; Fig. 3a, c). NNMT activity in the liver in-
creased progressively over the progression of MCT-induced
PAH (48.10 ± 4.095 and 56.48 ± 2.183 vs 40.26 ± 2.212 μmol
MNA/min/mg of wet liver tissue at 2 weeks and 4 weeks
for post-MCT and Control groups, respectively; Fig. 3c).Similarly, immunostaining revealed progressively increased
NNMT expression in post-MCT liver (Fig. 3d). In the
lungs, both NNMT activity and immunostaining showed
substantial increases; however, the progressive pattern and
parallel increase of NNMT activity and immunostaining
was less evident than in the liver (Fig. 3a, b).
Fig. 2 NO- and PGI2-dependent function in the isolated lung in PAH and systemic prostacyclin production. a Progressive impairment of L-NAME-
induced effect on the magnitude of hypoxic pulmonary vasoconstriction (HPV) in isolated blood-perfused lungs 1-4 weeks post-MCT, with no
changes in basal HPV; hypoxic ventilation with 5 % CO2 + 95 % N2 (Control n = 8, 2 weeks post-MCT n = 6, 4 weeks post-MCT n = 9); ΔPAP – the
change in Pulmonary Arterial Pressure. b Lack of changes of 6-keto-PGF1α concentration followed by a compensatory increase in 6-keto-PGF1α in
the effluents of isolated Krebs-Henseleit-perfused lungs at 2 and 4 weeks post-MCT, respectively (Control n = 15, 2 weeks post-MCT n = 12, 4 weeks
post-MCT n = 16). c Changes in 6-keto-PGF1α concentration: increased 6-keto-PGF1α in plasma 4 weeks post MCT (Control n = 15, 2 and 4 weeks
post-MCT n = 15). d Changes in ET-1 concentration in plasma of rats treated with MCT: increase at 2 and 4 weeks post MCT (Control n = 11, 2 weeks
post-MCT n = 12, 4 weeks post-MCT n = 18). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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metabolites in MCT-induced PAH
MNA concentration in plasma rose over the progres-
sion of PAH and was significantly higher 4 weeks
after MCT injection (0.38 ± 0.050 and 0.11 ± 0.021 μM
at 4 weeks for post-MCT and Control groups, re-
spectively, P < 0.05, n = 6-9) (Fig. 3e) while plasma
concentrations of nicotinamide was stable over the
course of PAH development (results not shown).
Concentrations of Met2PY in plasma were signifi-
cantly increased 4 weeks post MCT (Fig. 3f ), while
plasma concentrations of Met4PY were decreased at 2
and 4 weeks post MCT. Interestingly, the Met2PY/
Met4PY ratio changed considerably along the progres-
sion of PAH. This was due to a fall in Met4PY
2 weeks post MCT, and changes in Met2PY 4 weeks
post MCT (Fig. 3f ). There was a correlation between
MNA and PGI2 concentrations in plasma at 4 weeks
post MCT (r = 0.644, p = 0.06, n = 9).Changes in plasma concentration of MNA and its
metabolites in idiopathic pulmonary arterial
hypertension (IPAH)
We enrolled 10 IPAH patients and 8 controls. Most pa-
tients with IPAH were in WHO functional class 3 (n = 7),
the others in functional class 2 (n = 2) and 4 (n = 1). Con-
trol subjects did not have dyspnoea. The characteristics of
IPAH and Control groups is presented in Table 1.
MNA concentration in plasma was approximately 3
times higher in patients with IPAH as compared to
controls (MNA: 0.31 ± 0.101 and 0.11 ± 0.019 μM, re-
spectively, P < 0.01, n = 8-10) (Fig. 4a). Concentrations
of MNA metabolites did not differ between IPAH and
control groups (for Met2PY: 1.38 ± 0.339 and 1.11 ±
0.081 μM, respectively, n = 8-10; for Met4PY: 0.26 ±
0.078 and 0.17 ± 0.018 μM, respectively, n = 8-10,
Fig. 4b, c). Prostacyclin production assessed as con-
centration of 6-keto-PGF1α in plasma was also similar
for IPAH and Controls (Fig. 4d).
Fig. 3 Changes in NNMT pathway in MCT-induced pulmonary hypertension. a Increase in NNMT activity in the lungs at 2 and 4 weeks post MCT
(n = 4 in each group). b Increase in NNMT immunofluorescence in the lungs at 4 weeks post MCT (n = 3 in each group). c Increase in NNMT liver
activity and d immunointensity at 4 weeks post-MCT (n = 4 in each group). e Increase in plasma MNA concentration at 4 weeks post MCT (Control
n = 5, 2 weeks post-MCT n = 6, 4 weeks post-MCT n = 9). f Increase in Met2PY concentration at 4 weeks post MCT (Control n = 5, 2 weeks
post-MCT n = 6, 4 weeks post-MCT n = 9). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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In the present work, we demonstrated, to our knowledge
for the first time that pulmonary hypertension is associ-
ated with the activation of the NNMT-MNA pathway in
rats and in humans. We comprehensively characterized
MCT-induced PAH in rats by looking at the development
of right ventricular hypertrophy, right ventricular dys-
function, alterations in lung histopathology, lung ultra-
structure, and ET-1 plasma concentration—all changes
reported were fully compatible with the development of
PAH. Taking advantage of the isolated lung set-up, we also
found that PAH development was associated with im-
paired NO-dependent but not PGI2-dependent function.Most importantly, we demonstrated that over the course
of PAH development, NNMT activity progressively in-
creased in the liver and in the lungs, and that this re-
sponse was associated with increased MNA concentration
in plasma. In humans with newly diagnosed, treatment
naive IPAH MNA plasma concentration was also signifi-
cantly elevated supporting the notion that NNMT-MNA
pathway is activated not only in rats but also in humans in
the course of development of pulmonary hypertension.
The monocrotaline-induced model of PAH mimics
key features of human PH, for example increased ET-1
concentration in plasma, and a pro-inflammatory
pulmonary vascular response [24–32]. In our hands,
Table 1 Characteristics of IPAH patients and Control group
Parameter (units) IPAH patients, n=10 Controls, n=8 p
age (years) 41 (37-50) 54 (37-60) 0.24
sex (M) 3 (30 %) 3 (38 %) 0.87
NT-proBNP (pg/ml) 1204 (837-2327) 63 (28.5-135,4) 0.0002
ET-1 (ng/ml) 2.54 (2.06-2.79) 0.63 (0.49-0.86) 0.0002
6MWD (m) 397.5 (345-420) 460 (420-630) 0.02
Hb (g/dl) 15.4 (14.4-16.0) 13.3 (11.8-14.4) 0.01
PAP mean (mmHg) 52 (43-56) 12 (10-14.5) 0.0004
PWP (mmHg) 6 (3-8) 7.5 (6-9.5) 0.35
RAP mean (mmHg) 5 (4-7) 2 (2-3) 0.002
CI (l/min/m2) 1.9 (1.4-2.3) 3.2 (2.5-3.5) 0.002
PAR (dyn*s*cm-5) 1111 (888-1260) 77.9 (32.1-97.6) 0.0004
NT-proBNP N–terminal pro-brain natriuretic peptide, ET-1 endothelin-1, 6MWD
six minute walking distance, Hb hemoglobin, PAP mean mean pulmonary
arterial pressure, PWP pulmonary wedge pressure, RAP right atrial pressure,
CI cardiac index, PAR pulmonary arterial resistance
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in right ventricular end-diastolic volume and a significant
impairment of the right ventricular ejection fraction, as
well as with gradual increase in ET-1 concentration in
plasma [28, 33, 34]. Ultrastructural features of an injured
pulmonary endothelium, including a thickened basal
lamina, with neovascularization and fibrosis, were alsoFig. 4 MNA and 6-keto-PGF1α concentrations in plasma of patients with id
MNA in IPAH. b lack of changes of concentrations of Met2PY between IPA
between IPAH and Control groups. d lack of changes of concentrations of
groups. All data are presented as mean ± SEM; n = 8 for Control, n = 10 forcompatible with PAH [35–39]. These findings are in ac-
cordance with the previously described profile of MCT-
induced PAH in rats [27–29, 40] and provided a reli-
able background for profiling changes in NNMT-MNA
pathway activity and correlating them with changes in sys-
temic and pulmonary PGI2-dependent function.
Taking advantage of the isolated lung set-up we dem-
onstrated that NO-dependent endothelial function in the
pulmonary circulation was impaired while PGI2 release
from pulmonary circulation was not changed in the early
phase of PAH development and increased in advanced
PAH. Previously, other authors have reported decreased
or increased production of PGI2 during various stages of
PAH development [33, 40–44]. Our results tend to show
that early after MCT-injection, PGI2 production decreases
(results not shown), while in advanced PAH, it increases
[44] as a compensatory response to NO-deficient state.
Interestingly, the compensatory increase in PGI2 produc-
tion is a phenomenon often present in diseases showing
impaired NO-dependent function [45]. Although we
did not define the enzymatic sources of PGI2, in the
monocrotaline-modified rat lung, it is most likely
COX-2 [44, 46].
In the present work, we found that the development
of PAH was associated with a progressive increase in
NNMT activity/immunointensity and increased MNAiopathic pulmonary hypertension (IPAH). a increased concentration of
H and Control groups. c lack of changes of concentrations of Met4PY
stable prostacyclin metabolite, 6-keto-PGF1α between IPAH and Control
IPAH; ** P < 0.01
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not investigated but proinflammatory cytokines may be
involved e.g., IL-6 that increases in PAH, and was shown
to stimulate NNMT expression in the liver [25, 47]. On
the other hand, it could well be that an energy-failure-
related mechanism following hypoxia or metabolic stress
[48] in the lung may be involved in the activation of
NNMT in the lung in MCT-induced PAH [49, 50].
Increased NNMT in the lungs, most likely localized to
pulmonary epithelial and endothelial cells may be also
related to the increased cellular proliferation observed in
the MCT model [51, 52].
As the NNMT activity in the lungs was approximately
80-fold lower than in the liver, the major source of
MNA release responsible for the nearly 4-fold increase
in plasma MNA concentration seen in advanced PAH
may be most likely ascribed to the activation of the
NMMT-MNA pathway in the liver, despite the fact that
NNMT is also present in other tissues [1, 2]. Unexpect-
edly, only Met2PY but not Met4PY increased along with
MNA, suggesting modified function of aldehyde oxidase
by MCT metabolites in the liver [53, 54].
Obviously, we could not investigate the cellular source
of increased plasma MNA in patients with IPAH. Never-
theless we suspect that liver is the most likely source as
it is activated by pro-inflammatory stimuli present in pa-
tients with IPAH [55, 56].
We enrolled to the study only patients who were
newly diagnosed. Therefore we suspect that these pa-
tients were at relatively early stage of development of
pulmonary vascular disease. Most international registries
show that the mean time from the onset of symptoms to
diagnosis of IPAH is 18 months [57] however the time
from the onset of pulmonary vascular changes to the on-
set of dyspnoea in humans is unknown. Given the char-
acteristics of patients with IPAH, we could speculate
that they represent relatively early stage of PAH develop-
ment more or less compatible with the disease pheno-
type in MCT-induced PAH 2 weeks after MCT injection
but not 4 weeks after MCT that represented end-stage
of PAH. Accordingly, changes in MNA, Met2PY,
Met4PY and 6-keto-PGF1α in the comparative stage of
PAH development featured by approximately two folds
elevation of plasma ET-1 concentration were quite simi-
lar, displaying increased plasma MNA concentration
without changes in Met2PY, Met4PY and 6-keto-PGF1α
plasma concentration.
Exogenous MNA possesses anti-thrombotic and anti-
inflammatory activity mediated by the COX-2/PGI2 pathway
[58, 59]. MNA had also been shown to have gastroprotec-
tive, vasoprotective, hepatoprotective and anti-diabetic prop-
erties [17, 47, 60–63]. Still, the mechanisms of PGI2 release
by MNA remain unclear and PGI2 - independent mecha-
nisms of MNA action has been postulated [12, 14, 64].Although not explicitly, we have presented a relation-
ship between NNMT-MNA pathway activity and in-
creased plasma PGI2 concentration in the end-stage
PAH, suggesting a putative role of the NNMT metaboli-
te—endogenous MNA—in the stimulation of endogen-
ous PGI2 production.
Indeed, in the end stage of PAH in MCT model in rats
we found correlation between MNA and 6-keto-PGF1α
concentrations in plasma but not in early stage of MCT-
induced PAH or in IPAH in patients.
Conclusions
Progression of pulmonary hypertension in rats and
humans was associated with the activation of the
NNMT-MNA pathway. Given the vasoprotective activity
of exogenous MNA that was previously ascribed to PGI2
release, the activation of the endogenous NNMT-MNA
pathway described here may have a compensatory, pro-
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